Inactive Instrument
Claritas Pharmaceuticals Share Price Toronto S.E.
Stocks
KLY
CA1806341071
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 53.68L 38.31L 33.28L 30.9L 28.5L 37Cr 54.66L 3.66Cr 1.43Cr 18Cr 1.44Cr 1.41Cr 61Cr | P/E 2019 |
-0.74x | P/E 2020 | 0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 62.88L 44.88L 38.98L 36.2L 33.38L 43Cr 64.02L 4.29Cr 1.68Cr 21Cr 1.69Cr 1.65Cr 72Cr | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
99.74% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 day | +11.11% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CEO | Chief Executive Officer | 76 | 21/06/2017 |
Victoria Rudman
DFI | Director of Finance/CFO | 58 | 29/06/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CHM | Chairman | 76 | 18/03/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +11.11% | -.--% | - | - | 37 | |
| -0.80% | +5.16% | -0.70% | +12.87% | 4.89TCr | |
| -3.99% | +14.54% | +23.97% | +6.12% | 4.07TCr | |
| +4.70% | -0.13% | +409.27% | +618.12% | 3.85TCr | |
| -2.04% | -1.87% | +6.90% | +49.68% | 3.64TCr | |
| +5.56% | +11.70% | +11.64% | +51.50% | 2.84TCr | |
| -1.13% | -1.39% | - | - | 1.66TCr | |
| -1.23% | -4.51% | +32.14% | +128.50% | 1.63TCr | |
| -5.33% | -1.05% | -7.15% | -32.97% | 1.36TCr | |
| -0.06% | +3.75% | +3.81% | +9.62% | 1.36TCr | |
| Average | +0.76% | +6.06% | +59.99% | +105.43% | 2.81TCr | |
| Weighted average by Cap. | -0.04% | +7.20% | +75.03% | +125.59% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -2.12Cr -1.51Cr -1.31Cr -1.22Cr -1.13Cr -144.52Cr -2.16Cr -14Cr -5.66Cr -72Cr -5.68Cr -5.56Cr -241.38Cr | 42.1L 30.05L 26.1L 24.23L 22.35L 29Cr 42.86L 2.87Cr 1.12Cr 14Cr 1.13Cr 1.1Cr 48Cr |
| Net Debt | 7L 5L 4L 4L 4L 4.8Cr 7L 47.98L 18.78L 2.38Cr 18.87L 18.45L 8.01Cr | 9L 7L 6L 5L 5L 6.27Cr 9L 62.7L 24.55L 3.11Cr 24.66L 24.12L 10Cr |
Employees
-
